A study published in The Lancet found that patients with severe eosinophilic asthma controlled on bevacizumab can successfully taper their inhaled corticosteroids (ICS) without worsening asthma control. The study involved adults with severe eosinophilic asthma who tapered their high-dose ICS to a medium-dose, low-dose, and as-needed dose. The study found that 92 percent of patients were able to reduce their ICS with more than 60 percent reducing to anti-inflammatory reliever only without a change in asthma control. The rates of adverse events were similar between the groups, and the reductions in ICS were maintained during tapering.
Source link
Tapering of inhaled steroids feasible for asthma controlled with benralizumab
